Novel Approaches to Drug Discovery for PD
A collaboration with Elan Pharmaceuticals, Inc.
Total available funding: $1.5 million
Deadline: 6 p.m. ET, Tuesday, February 10, 2009
Funding Anticipated: July 2009
With a strong focus on the development of disease-modifying therapies for PD, Novel Approaches to Drug Discovery provides funding for projects of up to one year's duration. Ideal proposals will focus on efforts to develop promising biological targets into novel disease-modifying therapeutic strategies. Novel Approaches holds unique potential to provide awardees from both academic and biotech institutions with a clear opportunity for follow-on funding and collaboration for further development. Elan Pharmaceuticals, Inc., a neuroscience-based biotechnology company committed to developing novel approaches for neurodegenerative diseases, has an option for a right of first negotiation for any promising approaches or materials that arise out of this program. There is no pre-set budget limitation for applications under this initiative.
Therapeutics Development Initiative
Total available funding: $2.5 million, exclusively to industry
Deadline: 6 p.m. ET, Tuesday, January 20, 2009
Funding Anticipated: June 2009
The Therapeutics Development Initiative (TDI) seeks to stimulate
preclinical Parkinson's disease research projects of up to two years'
duration at for-profit institutions. There is no pre-set budget limitation
for applications under this initiative. The program prioritizes key and
critical preclinical studies necessary for developing, optimizing and
evaluating therapeutic str
|SOURCE The Michael J. Fox Foundation for Parkinson's Research|
Copyright©2008 PR Newswire.
All rights reserved